Figure INF-6:  Estimated HCV antibody prevalence among injecting drug users – studies with national and sub-national coverage – Part (v) All injecting drug users by gender, age, years of injecting and primary drug (where data is available)

Figure INF-06 part v

Notes:

By gender       

Available studies, median, average    

Countries with data available for the gender: Austria, Belgium, Cyprus, Czech Republic, Finland, Greece, Hungary, Italy, Malta, The Netherlands, Poland, Portugal, Slovenia, Slovakia, Turkey, United Kingdom

Number of samples: 410 (205 males; 205 females)  

Total sample size: 348406     

294480 (males); 53926 (females).        

By age          

Available studies, median and average         

Countries with data available for the age: Austria, Belgium, Cyprus, Czezh Republic, Finland, Greece, Hungary, Malta, The Netherlands, Poland, Portugal, Slovenia, Slovakia, Turkey, United Kingdom

Number of samples: 343 (120, <25); (115, 25-34); (108, >34).    

Total sample size: 36625       

11570 (<25); 15416 (25-34); 9639 (>34)      

By years of injection        

Available studies, average and median          

Countries with data available for years of injection: Austria, Belgium, Cyprus, Czech Republic, Greece, Poland, Portugal, Slovenia, Turkey, United Kingdom

Number of samples: 128 (59, <2 years); (69, >2 years) 

Total sample size: 29962      

8378 (<2 years); 21584 (>2 years)      

By opioids/non-opioids use    

Available studies, median and average        

Countries with data available for primary drug: Austria, Belgium, Cyprus, Czech Republic, Greece, Malta, Poland, Portugal, Slovenia, Turkey

Number of samples: 96 (52 opiates; 44 non-opiates)    

Total sample size: 7772         

1363 (non-opiates); 6409 (opiates)    

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points.